We study the human mucosal immune system with a focus on IBD and HIV to determine mechanisms of disease pathogenesis and predictors of therapeutic response
Out today the last piece of work that Maria Guillamot did in our lab in a collaboration with @AWeinstock and @DrShrutiNaik (who lead the study) showing type I interferon (IFN)-mediated activation of hematopoietic stem/progenitor cells resulting in profound changes to systemic host responses...such studies could impact the way that we connect inflammation, autoimmunity to hematopoietic stem cell biology, differentiation and dysfunction...
academic.oup.com/jimmunol/ar…
📢Thrilled to share our work on the ontogeny, reactivity, and function of #IgA subclasses in homeostasis and #IBD! Huge thanks to Andrea, all our amazing collaborators, and @JExpMed for their support throughout the extended revision process! It's time to celebrate🥳!
Tejedor Vaquero, Neuman, Mehr, Cerutti, @GMagri_Immuno@HMar_research et al. show that gut IgA1 & IgA2 subclasses co-emerge early in life, largely derive from clonally related and somatically mutated plasma cells in adults, & show unique changes in #IBS. hubs.la/Q02YM2zm0
Tejedor Vaquero, Neuman, Mehr, Cerutti, @GMagri_Immuno@HMar_research et al. show that gut IgA1 & IgA2 subclasses co-emerge early in life, largely derive from clonally related and somatically mutated plasma cells in adults, & show unique changes in #IBS. hubs.la/Q02YM2zm0
A fantastic day celebrating the 40th anniversary of the discovery of the TCR. Check out this T cell speaker photo which includes co-discoverers Tak Mak and Mark Davis. Thanks @UofT, @uoftmedicine, @ImmunologyUofT, @thePMCF for your support.
Please RT 🙏!📢My lab at @UniBarcelona is seeking a highly motivated postdoc to lead an exciting new public-private collaborative project (UB, CRG, CSIC, OrikineBio) aimed at testing a potentially game-changing therapy for IBD. If interested, please contact me at gmagri@ub.edu.
Very honored to receive the International @Inserm Prize today at the French Embassy in DC. Great evening with @Inserm CEO Didier Samuel, Ambassador Lilli, and wonderful colleagues, celebrating France/US partnerships and our shared commitment to advancing science across borders.
Bravo à @MiriamMerad chercheuse à l’Ecole de médecine du @MountSinaiNYC qui reçoit le #prixinternational 2024 de l’Inserm ! Il salue son travail exceptionnel en immunologie du #cancer et des maladies inflammatoires, symbole de la collaboration scientifique franco-américaine.
ALT Photo de Didier Samuel, Miriam Merad et Laurent Bili.
New research from @MehandruLab describes the depletion of germinal center B cells and IgA plasma cells in the #GI tracts of people living with #HIV. @francescacossa1
Read more in Science #Immunology: bit.ly/3Yd0Uwg
Celebrating our PI @NinaBhardwaj! What an amazing week; elected to the National Academy of Medicine on Monday, then selected as Inventor of the Year (Mount Sinai Innovation Awards)…we are all so proud to be in your lab! Cheers 🥂!
Every year, @JeanFredericCo1 hosts the GI Division #IBD Retreat to address challenging topics in #IBD. We're proud to keep the tradition going this year at IBD Retreat 2024! Register here to join: form.jotform.com/kalish39/IB…
🙏🏼🙏🏼🙏🏼pumped for the naik lab move to @SinaiImmunol and to be part of this vibrant and exciting community of immunologists and for the breakthrough discoveries we will make together @MiriamMerad@brianbrown#naiklabmoveuptown
🍾CONGRATULATIONS🍾 to the fantastic @DrShrutiNaik on winning this year's @LeoFondet award in recognition of her visionary skin research program encompassing dermatology, neuroimmunology and more! Read all about it >>> leo-foundation.org/en/2024/0…
🍾CONGRATULATIONS🍾 to the fantastic @DrShrutiNaik on winning this year's @LeoFondet award in recognition of her visionary skin research program encompassing dermatology, neuroimmunology and more! Read all about it >>> leo-foundation.org/en/2024/0…
How does vedolizumab work in ulcerative colitis patients?
Researchers in a new @SciImmunology study say the drug targets gut-associated lymphoid tissue. Learn more: scim.ag/6KJ
Explore Dr. Saurabh Mehandru's latest research uncovering vedolizumab's impact on gut-associated lymphoid tissue (#GALT) in #IBD treatment. Gain fresh insights into therapeutic response mechanisms:
bit.ly/3QiGUoJ
How does vedolizumab work in ulcerative colitis patients?
Researchers in a new @SciImmunology study say the drug targets gut-associated lymphoid tissue. Learn more: scim.ag/6Im